{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:41:37Z","timestamp":1793414497649,"version":"4.5.0"},"reference-count":399,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ymthe.2025.04.045","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T19:43:19Z","timestamp":1746474199000},"page":"2479-2516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":143,"title":["Current clinical applications of AAV-mediated gene therapy"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-1756","authenticated-orcid":false,"given":"Barry J.","family":"Byrne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Flanigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Matesanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan A.","family":"Waldrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora S.","family":"D'Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara K.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"B\u00f6nnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Carrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Rossano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lalaguna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Lara-Pezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sub","family":"Subramony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mercado-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Leon-Astudillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Ahrens-Nicklas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Bharucha-Goebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic J.","family":"Gessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuh-Liang","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Hsiu","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni-Chung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanford L.","family":"Boye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon E.","family":"Boye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey A.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.04.045_bib1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current Clinical Applications of In Vivo Gene Therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fpubh.2020.00058","article-title":"The financial impact of genetic diseases in a pediatric accountable care organization","volume":"8","author":"Miller","year":"2020","journal-title":"Front. Public Health"},{"key":"10.1016\/j.ymthe.2025.04.045_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2025.04.045_bib4","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41587-020-0642-9","volume":"38","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","article-title":"Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1","volume":"225","author":"Feldman","year":"2020","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymthe.2025.04.045_bib6","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.04.045_bib7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-Associated Virus Gene Therapy for Hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib8","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.04.045_bib9","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus integration: An integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","article-title":"Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations","volume":"25","author":"Mendell","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib12","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1006\/mthe.2001.0491","article-title":"Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males","volume":"4","author":"Arruda","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib14","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ymthe.2006.03.002","article-title":"Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial","volume":"13","author":"Schuettrumpf","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib15","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant","volume":"377","author":"George","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib16","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba9188","article-title":"MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates","volume":"12","author":"Hordeaux","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib19","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.04.045_bib20","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib23","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib24","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1212\/CON.0000000000001208","article-title":"The Dystrophinopathies","volume":"28","author":"Lee","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.ymthe.2025.04.045_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2025.04.045_bib26","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","article-title":"A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy","volume":"24","author":"Mah","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.04.045_bib27","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41431-022-01138-2","article-title":"Incidence of Duchenne muscular dystrophy in the modern era; an Australian study","volume":"30","author":"Kariyawasam","year":"2022","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2025.04.045_bib28","unstructured":"What is Duchenne? https:\/\/cureduchenne.org\/about\/what-is-duchenne\/."},{"key":"10.1016\/j.ymthe.2025.04.045_bib29","doi-asserted-by":"crossref","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production","volume":"90","author":"Charleston","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.04.045_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030778","article-title":"Recent trends in antisense therapies for duchenne muscular dystrophy","volume":"15","author":"Wilton-Clark","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2025.04.045_bib31","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41573-023-00775-6","article-title":"Therapeutic approaches for Duchenne muscular dystrophy","volume":"22","author":"Roberts","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.04.045_bib33","unstructured":"U.S. Food and Drug Administration. Center Director Decisional Memo (STN125781\/34). https:\/\/www.fda.gov\/media\/179485\/download."},{"key":"10.1016\/j.ymthe.2025.04.045_bib34","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib36","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/mus.27955","article-title":"Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1\/2a nonrandomized trial","volume":"69","author":"Mendell","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2025.04.045_bib38","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin Immunity after Gene Therapy for Duchenne\u2019s Muscular Dystrophy","volume":"388","author":"B\u00f6nnemann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib40","author":"Muntoni"},{"key":"10.1016\/j.ymthe.2025.04.045_bib42","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/JND-221639","article-title":"Meeting report: 2022 muscular dystrophy association summit on \u201csafety and challenges in gene transfer therapy\u201d","volume":"10","author":"Lek","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.04.045_bib44","unstructured":"3-Year Outcomes Update in the IGNITE DMD Phase 1\/2 Study of SGT-001 Microdystrophin Gene Therapy https:\/\/www.mdaconference.org\/abstract-library\/3-year-outcomes-update-in-the-ignite-dmd-phase-1-2-study-of-sgt-001-microdystrophin-gene-therapy\/."},{"key":"10.1016\/j.ymthe.2025.04.045_bib45","series-title":"The Mdx Mouse Model of Duchenne Muscular Dystrophy","article-title":"Systemic Delivery of SGT-003 Microdystrophin Gene Therapy Using the Novel Capsid AAV-SLB101 Ameliorates Muscle Pathology and Rescues Muscle Function","author":"Marshall","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.045_bib46","article-title":"RGX-202, an Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy","author":"Rocha","year":"2025","journal-title":"Interim Clinical Data"},{"key":"10.1016\/j.ymthe.2025.04.045_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2024.07.290","article-title":"410P GNT0004, Genethon\u2019s AAV8 vector-delivered microdystrophin gene therapy of Duchenne muscular dystrophy, first data of the phase I\/II part of the GNT-016-MDYF all-in-one clinical trial in ambulant boys","volume":"43","author":"Laugel","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.04.045_bib48","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne\u2019s Muscular Dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib49","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-024-07710-8","article-title":"Split intein-mediated protein trans-splicing to express large dystrophins","volume":"632","author":"Tasfaout","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.04.045_bib50","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1038\/s41467-024-50569-6","article-title":"Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.045_bib51","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12929-025-01123-z","article-title":"Treating neuromuscular diseases: unveiling gene therapy breakthroughs and pioneering future applications","volume":"32","author":"Wu","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ymthe.2025.04.045_bib52","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal muscular atrophy","volume":"8","author":"Mercuri","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2025.04.045_bib53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.04.045_bib54","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.04.045_bib55","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.04.045_bib56","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/hmg\/9.16.2451","article-title":"Animal models of spinal muscular atrophy","volume":"9","author":"Monani","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.04.045_bib57","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib58","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib59","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls","volume":"385","author":"Darras","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib60","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.04.045_bib61","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib62","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","article-title":"Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial","volume":"21","author":"Masson","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib63","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib64","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib65","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib66","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nmd.2023.11.010","article-title":"Continued safety and long-term effectiveness of onasemnogene abeparvovec in Ohio","volume":"34","author":"Waldrop","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.04.045_bib67","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","article-title":"Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue","volume":"27","author":"Thomsen","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib68","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib69","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/ijns10030058","article-title":"Newborn Screening for Spinal Muscular Atrophy: Variations in Practice and Early Management of Infants with Spinal Muscular Atrophy in the United States","volume":"10","author":"Zaidman","year":"2024","journal-title":"Int. J. Neonatal. Screen."},{"key":"10.1016\/j.ymthe.2025.04.045_bib71","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1177\/22143602241288095","article-title":"Newborn screening programs for spinal muscular atrophy worldwide in 2023","volume":"11","author":"Vr\u0161\u010daj","year":"2024","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.04.045_bib72","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JND-230122","article-title":"Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry","volume":"11","author":"Servais","year":"2024","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.04.045_bib73","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejpn.2024.08.006","article-title":"Outcomes for patients in the RESTORE registry with spinal muscular atrophy and four or more SMN2 gene copies treated with onasemnogene abeparvovec","volume":"53","author":"Tizzano","year":"2024","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib74","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41434-024-00456-y","article-title":"Gene replacement therapy for spinal muscular atrophy: safety and preliminary efficacy in a Brazilian cohort","volume":"31","author":"Mendon\u00e7a","year":"2024","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib75","article-title":"Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom","volume":"37","author":"Gowda","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.ymthe.2025.04.045_bib76","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","article-title":"Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy","volume":"44","author":"Day","year":"2021","journal-title":"Drug Saf."},{"key":"10.1016\/j.ymthe.2025.04.045_bib77","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","article-title":"Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib78","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: A case series","volume":"231","author":"Chand","year":"2021","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymthe.2025.04.045_bib79","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1212\/WNL.0000000000200676","article-title":"Child neurology: pathologically confirmed thrombotic microangiopathy caused by onasemnogene abeparvovec treatment for SMA","volume":"98","author":"Yazaki","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.04.045_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1259293","article-title":"High-sensitive cardiac troponin I (hs-cTnI) concentrations in newborns diagnosed with spinal muscular atrophy","volume":"11","author":"Johannsen","year":"2023","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.ymthe.2025.04.045_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2023.113493","article-title":"Necrotizing Enterocolitis following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series","volume":"260","author":"Gaillard","year":"2023","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymthe.2025.04.045_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/ph17030394","article-title":"Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma\u00ae) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System","volume":"17","author":"Ruggiero","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ymthe.2025.04.045_bib83","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib85","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/mus.27363","article-title":"Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy","volume":"64","author":"Kichula","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2025.04.045_bib86","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JND-221560","article-title":"Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)","volume":"10","author":"Finkel","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.04.045_bib87","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib88","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2020.167","article-title":"Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology","volume":"31","author":"Hordeaux","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib89","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","article-title":"Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit","volume":"24","author":"Van Alstyne","year":"2021","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2025.04.045_bib90","author":"Kwon"},{"key":"10.1016\/j.ymthe.2025.04.045_bib91","article-title":"Cost-Effectiveness of Technologies for the Treatment of Spinal Muscular Atrophy: A Systematic Review of Economic Studies","volume":"42","author":"Motta-Santos","year":"2024","journal-title":"Value Health Reg. Issues"},{"key":"10.1016\/j.ymthe.2025.04.045_bib92","doi-asserted-by":"crossref","first-page":"6544","DOI":"10.1007\/s00415-022-11319-0","article-title":"Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia","volume":"269","author":"Wang","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib93","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejpn.2024.06.001","article-title":"2024 update: European consensus statement on gene therapy for spinal muscular atrophy","volume":"51","author":"Kirschner","year":"2024","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib94","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1080\/13696998.2024.2346406","article-title":"Value-based payment and financing for cell and gene therapies: challenges and potential solutions","volume":"27","author":"Zhang","year":"2024","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.ymthe.2025.04.045_bib95","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/14737167.2023.2276374","article-title":"Payer and Developer perspectives on alternative payment models","volume":"24","author":"Moradian","year":"2024","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.ymthe.2025.04.045_bib96","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200224","article-title":"Life-Saving Treatments for Spinal Muscular Atrophy: Global Access and Availability","volume":"14","author":"Armengol","year":"2024","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.ymthe.2025.04.045_bib97","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ana.26299","article-title":"Ethical Perspectives on Treatment Options with Spinal Muscular Atrophy Patients","volume":"91","author":"Yeo","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib98","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/jcmm.14874","article-title":"Spinal muscular atrophy with respiratory distress type 1: Clinical phenotypes, molecular pathogenesis and therapeutic insights","volume":"24","author":"Saladini","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib99","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/brain\/77.2.169","article-title":"On the classification, natural history and treatment of the myopathies","volume":"77","author":"Walton","year":"1954","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.04.045_bib100","first-page":"702","article-title":"229th ENMC international workshop: Limb girdle muscular dystrophies - Nomenclature and reformed classification Naarden, the Netherlands, 17-19 March 2017. Neuromuscul","volume":"28","author":"Straub","year":"2018","journal-title":"Disord"},{"key":"10.1016\/j.ymthe.2025.04.045_bib101","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/CON.0000000000001178","article-title":"The Limb-Girdle Muscular Dystrophies","volume":"28","author":"Johnson","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.ymthe.2025.04.045_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12144769","article-title":"Limb-Girdle Muscular Dystrophies Classification and Therapies","volume":"12","author":"Bouchard","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib103","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/156652312802083585","article-title":"RNAi-based gene therapy for dominant Limb Girdle Muscular Dystrophies","volume":"12","author":"Liu","year":"2012","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib104","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.omtn.2018.10.004","article-title":"Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy","volume":"13","author":"Lee","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.04.045_bib105","article-title":"A gene-edited mouse model of limb-girdle muscular dystrophy 2C for testing exon skipping","volume":"13","author":"Demonbreun","year":"2019","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ymthe.2025.04.045_bib106","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.omtn.2023.05.017","article-title":"DNAJB6 isoform specific knockdown: Therapeutic potential for limb girdle muscular dystrophy D1","volume":"32","author":"Findlay","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.04.045_bib107","doi-asserted-by":"crossref","first-page":"8S18","DOI":"10.1016\/S0929-693X(23)00223-3","article-title":"Gene therapy for primary myopathies: literature review and prospects","volume":"30","author":"Querin","year":"2023","journal-title":"Arch. Pediatr."},{"key":"10.1016\/j.ymthe.2025.04.045_bib108","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene abeparvovec: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2025.04.045_bib109","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene moxeparvovec: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2025.04.045_bib110","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ymthe.2005.09.017","article-title":"Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A","volume":"13","author":"Bartoli","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib111","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/CIRCULATIONAHA.113.001340","article-title":"Restriction of calpain3 expression to the skeletal muscle prevents cardiac toxicity and corrects pathology in a murine model of limb-girdle muscular dystrophy","volume":"128","author":"Roudaut","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2025.04.045_bib112","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.omtm.2021.06.010","article-title":"Systemic delivery of AAVrh74.tMCK.hCAPN3 rescues the phenotype in a mouse model for LGMD2A\/R1","volume":"22","author":"Sahenk","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib113","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/hmg\/ddq065","article-title":"Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer","volume":"19","author":"Lostal","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.04.045_bib114","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1089\/hum.2017.062","article-title":"Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for Dysferlinopathy","volume":"29","author":"Potter","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib115","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/acn3.172","article-title":"Aav.dysferlin overlap vectors restore function in dysferlinopathy animal models","volume":"2","author":"Sondergaard","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib116","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1212\/01.wnl.0000306309.85301.e2","article-title":"Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D","volume":"71","author":"Rodino-Klapac","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.04.045_bib117","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/gt.2015.80","article-title":"\u03b2-Sarcoglycan gene transfer decreases fibrosis and restores force in LGMD2E mice","volume":"23","author":"Pozsgai","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib118","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/mthe.1999.0019","article-title":"Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer","volume":"1","author":"Cordier","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib119","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ana.22251","article-title":"Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D","volume":"68","author":"Mendell","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib120","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1089\/hum.2019.199","article-title":"Preclinical Systemic Delivery of Adeno-Associated \u03b1-Sarcoglycan Gene Transfer for Limb-Girdle Muscular Dystrophy","volume":"32","author":"Griffin","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib121","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ymthe.2017.02.013","article-title":"Systemic AAV-Mediated \u03b2-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E Mice","volume":"25","author":"Pozsgai","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib122","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.omtm.2019.04.007","article-title":"An AAV-SGCG Dose-Response Study in a \u03b3-Sarcoglycanopathy Mouse Model in the Context of Mechanical Stress","volume":"13","author":"Israeli","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib123","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.omtm.2023.01.004","article-title":"Systemic \u03b3-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C\/R5 mouse model","volume":"28","author":"Seo","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib124","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/hmg\/ddab260","article-title":"CFTR corrector C17 is effective in muscular dystrophy, in vivo proof of concept in LGMDR3","volume":"31","author":"Scano","year":"2022","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.04.045_bib125","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1038\/mt.2014.141","article-title":"Muscle and heart function restoration in a limb girdle muscular dystrophy 2I (LGMD2I) mouse model by systemic FKRP gene delivery","volume":"22","author":"Qiao","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib126","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/mt.2013.156","article-title":"Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of \u03b1-dystroglycan and improves muscle functions","volume":"21","author":"Xu","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib127","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1093\/hmg\/ddx066","article-title":"AAV-mediated transfer of FKRP shows therapeutic efficacy in a murine model but requires control of gene expression","volume":"26","author":"Gicquel","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.04.045_bib128","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1016\/j.ymthe.2023.10.022","article-title":"Improved efficacy of FKRP AAV gene therapy by combination with ribitol treatment for LGMD2I","volume":"31","author":"Cataldi","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib129","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/mt.2016.40","article-title":"Precise correction of disease mutations in induced pluripotent stem cells derived from patients with limb girdle muscular dystrophy","volume":"24","author":"Turan","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib130","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.omtn.2023.02.005","article-title":"Cas9-induced single cut enables highly efficient and template-free repair of a muscular dystrophy causing founder mutation","volume":"31","author":"M\u00fcthel","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.04.045_bib131","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.omtm.2019.10.002","article-title":"Plasmid-Mediated Gene Therapy in Mouse Models of Limb Girdle Muscular Dystrophy","volume":"15","author":"Guha","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib132","doi-asserted-by":"crossref","first-page":"15060","DOI":"10.1073\/pnas.212498399","article-title":"The lipid phosphatase myotubularin is essential for skeletal muscle maintenance but not for myogenesis in mice","volume":"99","author":"Buj-Bello","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.04.045_bib133","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/ng0696-175","article-title":"A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast","volume":"13","author":"Laporte","year":"1996","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.04.045_bib134","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/mus.26018","article-title":"A multicenter, retrospective medical record review of X-linked myotubular myopathy: The recensus study","volume":"57","author":"Beggs","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2025.04.045_bib135","doi-asserted-by":"crossref","first-page":"e1852","DOI":"10.1212\/WNL.0000000000007319","article-title":"X-linked myotubular myopathy: A prospective international natural history study","volume":"92","author":"Annoussamy","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.04.045_bib136","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1093\/hmg\/ddn112","article-title":"AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis","volume":"17","author":"Buj-Bello","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.04.045_bib137","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2017.02.004","article-title":"Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs","volume":"25","author":"Mack","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib138","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/mus.25658","article-title":"Long-term effects of systemic gene therapy in a canine model of myotubular myopathy","volume":"56","author":"Elverman","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2025.04.045_bib139","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","article-title":"Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial","volume":"22","author":"Shieh","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib140","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/s12931-024-02966-0","article-title":"An algorithm for discontinuing mechanical ventilation in boys with x-linked myotubular myopathy after positive response to gene therapy: the ASPIRO experience","volume":"25","author":"Graham","year":"2024","journal-title":"Respir. Res."},{"key":"10.1016\/j.ymthe.2025.04.045_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104894","article-title":"Effects of gene replacement therapy with resamirigene bilparvovec (AT132) on skeletal muscle pathology in X-linked myotubular myopathy: results from a substudy of the ASPIRO open-label clinical trial","volume":"99","author":"Lawlor","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2025.04.045_bib142","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/j.ajhg.2023.08.008","article-title":"High-throughput transcriptome analyses from ASPIRO, a phase 1\/2\/3 study of gene replacement therapy for X-linked myotubular myopathy","volume":"110","author":"Andreoletti","year":"2023","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2025.04.045_bib143","author":"Shieh"},{"key":"10.1016\/j.ymthe.2025.04.045_bib144","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166275","article-title":"Loss of Mtm1 causes cholestatic liver disease in a model of X-linked myotubular myopathy","volume":"133","author":"Karolczak","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.04.045_bib146","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.04.045_bib147","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1055\/s-0041-1722862","article-title":"Gene therapy for inherited bleeding disorders","volume":"47","author":"Arruda","year":"2021","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.ymthe.2025.04.045_bib148","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41434-020-00218-6","article-title":"Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor","volume":"30","author":"Barbon","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib149","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2011-09-377630","article-title":"AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage","volume":"119","author":"Binny","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.045_bib150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910336","article-title":"A Novel Murine Model Enabling rAAV8-PC Gene Therapy for Severe Protein C Deficiency","volume":"25","author":"Levy-Mendelovich","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2025.04.045_bib151","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib152","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib153","series-title":"Summary Basis for Regulatory Action: Valoctocogene Roxaparvovec-Rvox","year":"2023"},{"key":"10.1016\/j.ymthe.2025.04.045_bib154","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1182\/bloodadvances.2023011847","article-title":"Roctavian gene therapy for hemophilia A","volume":"8","author":"Samelson-Jones","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.04.045_bib155","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","article-title":"Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B","volume":"391","author":"Cuker","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib156","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib157","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1182\/bloodadvances.2023010511","article-title":"Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec","volume":"8","author":"Anguela","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.04.045_bib158","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.2019003777","article-title":"Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues","volume":"138","author":"Leebeek","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.045_bib159","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jtha.2023.12.005","article-title":"Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia","volume":"22","author":"Pierce","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.04.045_bib160","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood-2023-172845","article-title":"Gene Therapy Expressing Platelet-Derived Factor VIII for Correction of Hemophilia \u0391 with a History of Inhibitors","volume":"142","author":"Wilcox","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.045_bib161","doi-asserted-by":"crossref","first-page":"38345","DOI":"10.1074\/jbc.M206959200","article-title":"High level expression of recombinant porcine coagulation factor VIII","volume":"277","author":"Doering","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.04.045_bib162","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood-2024-202882","article-title":"Factor VIII Expression from a Novel F8 Transgene through a Lentiviral Vector Transduced CD34+ Autologous Hematopoietic Stem Cells for Gene Therapy of Severe Hemophilia \u0391: Final Results from a Phase 1 Clinical Trial","volume":"144","author":"Srivastava","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.045_bib163","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJMoa2410597","article-title":"Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A","volume":"392","author":"Srivastava","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib164","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1038\/s41467-022-30102-3","article-title":"Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates","volume":"13","author":"Milani","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.045_bib165","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis (2014). Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.04.045_bib166","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.1073\/pnas.79.21.6461","article-title":"Isolation and characterization of a cDNA coding for human factor IX","volume":"79","author":"Kurachi","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.04.045_bib167","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1182\/blood-2014-02-555151","article-title":"A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII","volume":"123","author":"Fahs","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.045_bib168","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1182\/blood-2014-02-554501","article-title":"Murine coagulation factor VIII is synthesized in endothelial cells","volume":"123","author":"Everett","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.045_bib169","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias--from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2025.04.045_bib171","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib172","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bjh.14072","article-title":"Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study","volume":"174","author":"Schrijvers","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib173","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/hae.12683","article-title":"Transition considerations for extended half-life factor products","volume":"21","author":"Croteau","year":"2015","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2025.04.045_bib174","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood-2016-02-683169","article-title":"Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project","volume":"129","author":"Manco-Johnson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.045_bib175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2012.02822.x","article-title":"WFH: closing the global gap--achieving optimal care","volume":"18","author":"Skinner","year":"2012","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2025.04.045_bib176","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib177","article-title":"Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity","volume":"5","author":"Samelson-Jones","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.04.045_bib178","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.04.045_bib180","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1182\/bloodadvances.2022008886","article-title":"Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy","volume":"7","author":"von Drygalski","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.04.045_bib181","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2352-3026(24)00006-1","article-title":"Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial","volume":"11","author":"Coppens","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib182","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1182\/blood-2021-150541","article-title":"Follow-up of More Than 5 Years in a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec Adeno-Associated Virus Gene Therapy","volume":"138","author":"Samelson-Jones","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.045_bib183","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib184","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2147\/JBM.S371438","article-title":"Gene Therapy and Hemophilia: Where Do We Go from Here? J","volume":"13","author":"Bolous","year":"2022","journal-title":"Blood Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib185","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib186","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.2022018971","article-title":"Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1\/2 Alta study","volume":"143","author":"Leavitt","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.045_bib187","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/hae.14936","article-title":"Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment","volume":"30","author":"Symington","year":"2024","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2025.04.045_bib188","author":"Huang"},{"key":"10.1016\/j.ymthe.2025.04.045_bib189","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1432-1033.1995.tb20776.x","article-title":"Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization","volume":"232","author":"Lind","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ymthe.2025.04.045_bib190","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1182\/blood.2023023275","article-title":"Coagulation factor VIII: biological basis of emerging hemophilia A therapies","volume":"144","author":"Samelson-Jones","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.045_bib191","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.045_bib192","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/blood-2023-180803","article-title":"GO-8: Stable Expression of Factor VIII over 5 Years Following Adeno-Associated Gene Transfer in Subjects with Hemophilia a Using a Novel Human Factor VIII Variant","volume":"142","author":"Chowdary","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.045_bib193","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1182\/blood-2021-148661","article-title":"First-in-Human Dose-Finding Study of AAVhu37 Vector-Based Gene Therapy: BAY 2599023 Has Stable and Sustained Expression of FVIII over 2 Years","volume":"138","author":"Pipe","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.045_bib194","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib195","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib196","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1182\/bloodadvances.2023011366","article-title":"Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A","volume":"7","author":"Agosti","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.04.045_bib197","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","article-title":"Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels","volume":"17","author":"den Uijl","year":"2011","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2025.04.045_bib198","author":"Ozelo"},{"key":"10.1016\/j.ymthe.2025.04.045_bib199","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood-2024-208486","article-title":"Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia \u0391: Primary Analysis Results from the Phase 3 \u0391FFINE Gene Therapy Trial","volume":"144","author":"Leavitt","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.045_bib201","author":"Pipe"},{"key":"10.1016\/j.ymthe.2025.04.045_bib202","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib203","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101205","article-title":"AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of life","volume":"32","author":"Doshi","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib204","doi-asserted-by":"crossref","first-page":"7193","DOI":"10.1038\/s41467-024-51296-8","article-title":"Pre-clinical evaluation of an enhanced-function factor VIII variant for durable hemophilia A gene therapy in male mice","volume":"15","author":"Sternberg","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.045_bib205","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1016\/j.ymthe.2022.11.001","article-title":"Vector genome loss and epigenetic modifications mediate decline in transgene expression of AAV5 vectors produced in mammalian and insect cells","volume":"30","author":"Handyside","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib206","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.omtm.2018.12.007","article-title":"Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy","volume":"12","author":"Samelson-Jones","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib207","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1182\/blood.2020007562","article-title":"Activated protein C has a regulatory role in factor VIII function","volume":"137","author":"Wilhelm","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.045_bib208","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2023-178106","article-title":"Evolution Directed Gene Engineering (EDGE) Identifies Single Amino Acid Substitutions in FVIII with Six-Fold Increased in Vitro and In Vivo Activity","volume":"142","author":"Van Gorder","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.045_bib209","article-title":"Overcoming Hemophilia A Gene Therapy Limitations with an Enhanced Function Factor VIII Variant","author":"Sternberg","year":"2024","journal-title":"bioRxiv."},{"key":"10.1016\/j.ymthe.2025.04.045_bib211","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1073\/pnas.97.2.793","article-title":"Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure","volume":"97","author":"Miyamoto","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.04.045_bib212","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1161\/01.CIR.95.2.423","article-title":"Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes","volume":"95","author":"Hajjar","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2025.04.045_bib213","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.04.045_bib214","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cardfail.2009.01.013","article-title":"Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1\/2 clinical trial","volume":"15","author":"Jaski","year":"2009","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ymthe.2025.04.045_bib215","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","article-title":"Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure","volume":"124","author":"Jessup","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2025.04.045_bib216","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00431-005-1678-z","article-title":"Familial X-linked cardiomyopathy (Danon disease): diagnostic confirmation by mutation analysis of the LAMP2gene","volume":"164","author":"Balmer","year":"2005","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymthe.2025.04.045_bib217","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/GIM.0b013e31820ad795","article-title":"Natural history of Danon disease","volume":"13","author":"Boucek","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib218","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/CIRCHEARTFAILURE.114.001105","article-title":"Danon disease: clinical features, evaluation, and management","volume":"7","author":"D\u2019souza","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ymthe.2025.04.045_bib219","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1073\/pnas.1808618116","article-title":"LAMP-2B regulates human cardiomyocyte function by mediating autophagosome-lysosome fusion","volume":"116","author":"Chi","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.04.045_bib220","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax1744","article-title":"Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease","volume":"12","author":"Manso","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib221","series-title":"Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trialof RP-A501 in Danon Disease | Rocket Pharmaceuticals","year":"2021"},{"key":"10.1016\/j.ymthe.2025.04.045_bib222","series-title":"Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trialfor RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA)Annual Scientific Meeting 2022 | Rocket Pharmaceuticals","year":"2022"},{"key":"10.1016\/j.ymthe.2025.04.045_bib223","series-title":"Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 TrialDesign for RP-A501 in Danon Disease | Rocket Pharmaceuticals","year":"2023"},{"key":"10.1016\/j.ymthe.2025.04.045_bib224","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1056\/NEJMoa2412392","article-title":"Phase 1 study of AAV9.LAMP2B gene therapy in danon disease","volume":"392","author":"Greenberg","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib225","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJMra1509267","article-title":"Arrhythmogenic right ventricular cardiomyopathy","volume":"376","author":"Corrado","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib226","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198801213180301","article-title":"Right ventricular cardiomyopathy and sudden death in young people","volume":"318","author":"Thiene","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib227","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jacc.2018.05.065","article-title":"Clinical Diagnosis, Imaging, and Genetics of Arrhythmogenic Right Ventricular Cardiomyopathy\/Dysplasia: JACC State-of-the-Art Review","volume":"72","author":"Gandjbakhch","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib228","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1161\/CIRCRESAHA.107.154252","article-title":"Connexin43 remodeling caused by inhibition of plakophilin-2 expression in cardiac cells","volume":"101","author":"Oxford","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.ymthe.2025.04.045_bib229","article-title":"Transcriptomic coupling of PKP2 with inflammatory and immune pathways endogenous to adult cardiac myocytes","volume":"11","author":"P\u00e9rez-Hern\u00e1ndez","year":"2020","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib230","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.123.004305","article-title":"AAV-Mediated Delivery of Plakophilin-2a Arrests Progression of Arrhythmogenic Right Ventricular Cardiomyopathy in Murine Hearts: Preclinical Evidence Supporting Gene Therapy in Humans","volume":"17","author":"van Opbergen","year":"2024","journal-title":"Circ. Genom. Precis. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib231","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s44161-023-00370-3","article-title":"Plakophilin 2 gene therapy prevents and rescues arrhythmogenic right ventricular cardiomyopathy in a mouse model harboring patient genetics","volume":"2","author":"Bradford","year":"2023","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.ymthe.2025.04.045_bib232","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s44161-023-00378-9","article-title":"Therapeutic efficacy of AAV-mediated restoration of PKP2 in arrhythmogenic cardiomyopathy","volume":"2","author":"Kyriakopoulou","year":"2023","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.ymthe.2025.04.045_bib233","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s43856-024-00450-w","article-title":"AAV9:PKP2 improves heart function and survival in a Pkp2-deficient mouse model of arrhythmogenic right ventricular cardiomyopathy","volume":"4","author":"Wu","year":"2024","journal-title":"Commun. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib234","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1126\/science.1223602","article-title":"Molecular mechanics of cardiac myosin-binding protein C in native thick filaments","volume":"337","author":"Previs","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.04.045_bib235","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1400205","article-title":"Myosin-binding protein C corrects an intrinsic inhomogeneity in cardiac excitation-contraction coupling","volume":"1","author":"Previs","year":"2015","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2025.04.045_bib236","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2025.04.045_bib237","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.cardfail.2023.11.010","article-title":"MyPeak-1: A Phase 1b Study to Evaluate Safety and Efficacy of TN-201, an Adeno-Associated Virus Serotype 9 (AAV9) Investigational Gene Therapy, in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy (HCM)","volume":"30","author":"Haroldson","year":"2024","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ymthe.2025.04.045_bib238","article-title":"Gene Therapy Mediates Therapeutic Improvement in Cardiac Hypertrophy and Survival in a Murine Model of MYBPC3 -Associated Cardiomyopathy","author":"Greer-Short","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2025.04.045_bib239","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40265-023-01874-9","article-title":"Omaveloxolone: First Approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2025.04.045_bib240","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1038\/s41596-023-00875-y","article-title":"Structure-guided AAV capsid evolution strategies for enhanced CNS gene delivery","volume":"18","author":"Gonzalez","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2025.04.045_bib241","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/hum.2017.026","article-title":"Evaluation of Intrathecal Routes of Administration for Adeno-Associated Viral Vectors in Large Animals","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib242","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/hmg\/ddy427","article-title":"Correction of half the cardiomyocytes fully rescue Friedreich ataxia mitochondrial cardiomyopathy through cell-autonomous mechanisms","volume":"28","author":"Belbellaa","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.04.045_bib243","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.ymthe.2018.05.006","article-title":"Rapid and complete reversal of sensory ataxia by gene therapy in a novel model of friedreich ataxia","volume":"26","author":"Piguet","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib244","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.omtm.2020.08.018","article-title":"High levels of frataxin overexpression lead to mitochondrial and cardiac toxicity in mouse models","volume":"19","author":"Belbellaa","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib246","author":"Phase"},{"key":"10.1016\/j.ymthe.2025.04.045_bib248","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2025.04.045_bib249","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1089\/hum.2024.182","article-title":"Twenty-Year Survival Analysis of Adeno-Associated Virus Vector Serotype 2-Mediated Gene Therapy to the Central Nervous System for CLN2 Disease","volume":"36","author":"Sondhi","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib250","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5413","article-title":"Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2","volume":"12","author":"Sondhi","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib251","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: Management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.04.045_bib252","doi-asserted-by":"crossref","DOI":"10.3390\/ph16020320","article-title":"Treatment of fabry disease: established and emerging therapies","volume":"16","author":"Umer","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ymthe.2025.04.045_bib253","series-title":"Sangamo Therapeutics Announces Updated Phase 1\/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile | Sangamo Therapeutics","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.045_bib255","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","article-title":"Pompe disease: from basic science to therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymthe.2025.04.045_bib256","article-title":"An analysis of Pompe newborn screening data: a new prevalence at birth, insight and discussion","volume":"11","author":"Colburn","year":"2023","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.ymthe.2025.04.045_bib257","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","article-title":"Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling","volume":"7","author":"Ausems","year":"1999","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2025.04.045_bib258","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1152\/jn.00190.2021","article-title":"Case Studies in Neuroscience: Neuropathology and diaphragm dysfunction in ventilatory failure from late-onset Pompe disease","volume":"126","author":"Fuller","year":"2021","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib259","doi-asserted-by":"crossref","first-page":"290","DOI":"10.21037\/atm.2019.05.56","article-title":"Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy","volume":"7","author":"Byrne","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib260","doi-asserted-by":"crossref","first-page":"289","DOI":"10.21037\/atm.2019.04.49","article-title":"An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond","volume":"7","author":"Korlimarla","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib261","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.resp.2013.06.007","article-title":"The respiratory neuromuscular system in Pompe disease","volume":"189","author":"Fuller","year":"2013","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib262","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib263","first-page":"506","article-title":"Late-onset Pompe\u2019s disease","volume":"32","author":"Teener","year":"2012","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib264","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-6-34","article-title":"Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy","volume":"6","author":"G\u00fcng\u00f6r","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2025.04.045_bib265","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54314-8","article-title":"Dynamic respiratory muscle function in late-onset Pompe disease","volume":"9","author":"Smith","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.04.045_bib266","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ymgme.2013.06.023","article-title":"Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function","volume":"110","author":"Gaeta","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.04.045_bib267","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2022.10.010","article-title":"Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report","volume":"25","author":"Kishnani","year":"2023","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib268","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","article-title":"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial","volume":"20","author":"Schoser","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib269","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijcard.2023.03.010","article-title":"Effects of enzyme replacement therapy on cardiac function in classic infantile Pompe disease","volume":"380","author":"Scheffers","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib270","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2024.1310317","article-title":"Efficacy and safety of enzyme replacement therapy with alglucosidase alfa for the treatment of patients with infantile-onset Pompe disease: a systematic review and metanalysis","volume":"12","author":"Dornelles","year":"2024","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.ymthe.2025.04.045_bib271","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/jimd.12736","article-title":"Long term survival in patients with classic infantile Pompe disease reveals a spectrum with progressive brain abnormalities and changes in cognitive functioning","volume":"47","author":"van den Dorpel","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2025.04.045_bib272","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1017\/S1047951121002079","article-title":"Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohort","volume":"32","author":"Byrne","year":"2022","journal-title":"Cardiol. Young"},{"key":"10.1016\/j.ymthe.2025.04.045_bib273","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10214828","article-title":"A Systematic Review and Meta-Analysis of Enzyme Replacement Therapy in Late-Onset Pompe Disease","volume":"10","author":"Dornelles","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib274","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jpeds.2013.03.002","article-title":"B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease","volume":"163","author":"Elder","year":"2013","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymthe.2025.04.045_bib275","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.04.045_bib276","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib277","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/JND-190426","article-title":"Advancements in AAV-mediated Gene Therapy for Pompe Disease","volume":"7","author":"Salabarria","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.04.045_bib278","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1089\/hum.2010.245","article-title":"Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors","volume":"22","author":"Gray","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib279","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1479-0556-6-13","article-title":"Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice","volume":"6","author":"Pacak","year":"2008","journal-title":"Genet. Vaccin. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib280","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/sj.mt.6300027","article-title":"Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle","volume":"15","author":"Salva","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib281","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ymthe.2006.08.001","article-title":"Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II","volume":"14","author":"Sun","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib282","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.omtm.2018.11.002","article-title":"AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice","volume":"12","author":"Colella","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib283","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.ymthe.2023.02.014","article-title":"Phase I study of liver depot gene therapy in late-onset Pompe disease","volume":"31","author":"Smith","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib284","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.expneurol.2016.07.013","article-title":"Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: Clinical evidence of respiratory plasticity","volume":"287","author":"Smith","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib285","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1038\/s41467-022-33745-4","article-title":"Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing","volume":"13","author":"Gonzalez","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.045_bib286","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/hum.2018.016","article-title":"Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease","volume":"30","author":"Keeler","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib287","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1094279","article-title":"Immune transgene-dependent myocarditis in macaques after systemic administration of adeno-associated virus expressing human acid alpha-glucosidase","volume":"14","author":"Hordeaux","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib288","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/WCO.0000000000001187","article-title":"Current avenues of gene therapy in Pompe disease","volume":"36","author":"Leon-Astudillo","year":"2023","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib289","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes","volume":"24","author":"Smith","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib290","first-page":"208","article-title":"Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease. Hum. Gene Ther. Clin","volume":"28","author":"Corti","year":"2017","journal-title":"Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib291","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/humc.2014.2514","article-title":"Phase I\/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV-GAA) gene vector in patients with Pompe disease","volume":"25","author":"Byrne","year":"2014","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib292","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/humc.2015.068","article-title":"Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning","volume":"26","author":"Corti","year":"2015","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib293","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41588-018-0090-3","article-title":"Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression","volume":"50","author":"Wray","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.04.045_bib295","series-title":"MDA Clinical & Scientific Conference","article-title":"Two-year safety and exploratory efficacy of AT845 gene replacement therapy for late onset Pompe disease: FORTIS, a phase 1\/2 open-label clinical study","author":"Mozaffar","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.045_bib297","article-title":"First-in-human case report: AAV9-hGAA gene therapy for a patient with infantile-onset Pompe disease","author":"Ma","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.ymthe.2025.04.045_bib298","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40478-017-0464-2","article-title":"Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease","volume":"5","author":"Hordeaux","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.ymthe.2025.04.045_bib299","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/mt.2011.214","article-title":"Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice","volume":"20","author":"Qiu","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib300","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1152\/jn.00026.2022","article-title":"Chemogenetic activation of hypoglossal motoneurons in a mouse model of Pompe disease","volume":"128","author":"Singer","year":"2022","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib301","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.omtm.2020.04.023","article-title":"Lentiviral hematopoietic stem cell gene therapy corrects murine pompe disease","volume":"17","author":"Stok","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib302","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.omtm.2022.09.010","article-title":"IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy","volume":"27","author":"Liang","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib303","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.omtm.2022.10.017","article-title":"Screening chimeric GAA variants in preclinical study results in hematopoietic stem cell gene therapy candidate vectors for Pompe disease","volume":"27","author":"Dogan","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib304","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/jgm.1305","article-title":"Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease","volume":"11","author":"Douillard-Guilloux","year":"2009","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib305","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","article-title":"Overview of the mucopolysaccharidoses","volume":"50","author":"Muenzer","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ymthe.2025.04.045_bib306","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/jimd.12615","article-title":"Advances in therapies for neurological lysosomal storage disorders","volume":"46","author":"Ellison","year":"2023","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2025.04.045_bib307","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa2106596","article-title":"Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome","volume":"385","author":"Gentner","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib308","doi-asserted-by":"crossref","first-page":"11830","DOI":"10.1073\/pnas.90.24.11830","article-title":"Metabolic correction and cross-correction of mucopolysaccharidosis type II (Hunter syndrome) by retroviral-mediated gene transfer and expression of human iduronate-2-sulfatase","volume":"90","author":"Braun","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.04.045_bib309","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13023-021-01880-8","article-title":"Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities","volume":"16","author":"Puckett","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2025.04.045_bib310","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1016\/j.ymthe.2022.10.010","article-title":"First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I\/II and hemophilia B","volume":"30","author":"Harmatz","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib311","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107416","article-title":"Rgx-111 gene therapy for the treatment of severe mucopolysaccharidosis type i (mps i): interim analysis of data from the first in human study","volume":"138","author":"Gilmor","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.04.045_bib312","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108245","article-title":"CAMPSIITETM Phase I\/II\/III: An interim clinical study update of RGX-121, an investigational gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II)","volume":"141","author":"Pisani","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.04.045_bib313","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib314","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/j.ymgme.2018.12.283","article-title":"Design and rationale of the LYS-SAF302 gene therapy study in mucopolysaccharidosis type IIIA (MPS IIIA) children","volume":"126","author":"Olivier","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.04.045_bib315","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.94.15_supplement.5175","article-title":"Safety, Tolerability, and Preliminary Evidence of Biopotency in Transpher B, a Multicenter, Singledose, Phase 1\/2 Clinical Trial of ABO-101 Gene Therapy for Sanfilippo Syndrome Type B (Mucopolysaccharidosis IIIB) (5175)","volume":"94","author":"McBride","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.04.045_bib316","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.98.18_supplement.213","article-title":"Updated results of Transpher A, a multicenter, single-dose, Phase 1\/2 clinical trial of ABO-102 investigational gene therapy for Sanfilippo syndrome type A (mucopolysaccharidosis IIIA) (S39.008)","volume":"98","author":"Flanigan","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.04.045_bib317","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108535","article-title":"Community consensus for Heparan sulfate as a biomarker to support accelerated approval in Neuronopathic Mucopolysaccharidoses","volume":"142","author":"Muenzer","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.04.045_bib318","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib319","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.molmed.2022.01.003","article-title":"AAV capsid design: A Goldilocks challenge","volume":"28","author":"Zolotukhin","year":"2022","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib320","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41591-021-01664-4","article-title":"AAV gene therapy for Tay-Sachs disease","volume":"28","author":"Flotte","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib322","series-title":"GeneReviews\u00ae [Internet]","article-title":"GAN-Related Neurodegeneration","author":"Opal","year":"2003"},{"key":"10.1016\/j.ymthe.2025.04.045_bib323","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/81701","article-title":"The gene encoding gigaxonin, a new member of the cytoskeletal BTB\/kelch repeat family, is mutated in giant axonal neuropathy","volume":"26","author":"Bomont","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.04.045_bib324","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1093\/brain\/awab179","article-title":"Giant axonal neuropathy: cross-sectional analysis of a large natural history cohort","volume":"144","author":"Bharucha-Goebel","year":"2021","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.04.045_bib325","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/mus.24321","article-title":"Giant axonal neuropathy: An updated perspective on its pathology and pathogenesis","volume":"50","author":"Johnson-Kerner","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2025.04.045_bib326","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/gt.2011.130","article-title":"Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs","volume":"19","author":"Federici","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib327","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib328","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1089\/hum.2011.008","article-title":"Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery","volume":"22","author":"Snyder","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib329","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.omtm.2018.02.005","article-title":"Development of intrathecal AAV9 gene therapy for giant axonal neuropathy","volume":"9","author":"Bailey","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib330","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa2307952","article-title":"Intrathecal gene therapy for giant axonal neuropathy","volume":"390","author":"Bharucha-Goebel","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib331","first-page":"884","article-title":"261st ENMC International Workshop: Management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The Netherlands. Neuromuscul","volume":"33","author":"Servais","year":"2023","journal-title":"Disord"},{"key":"10.1016\/j.ymthe.2025.04.045_bib332","article-title":"A Patient-Centered Evaluation of Meaningful Change on the 32-Item Motor Function Measure in Spinal Muscular Atrophy Using Qualitative and Quantitative Data","volume":"12","author":"Duong","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib333","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.apmr.2020.10.116","article-title":"Responsiveness and Minimal Clinically Important Difference of the Motor Function Measure in Collagen VI-Related Dystrophies and Laminin Alpha2-Related Muscular Dystrophy","volume":"102","author":"Le Goff","year":"2021","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.ymthe.2025.04.045_bib334","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/archneurpsyc.1931.02230020085005","article-title":"SCHILDER\u2019S ENCEPHALITIS PERIAXIALIS DIFFUSA","volume":"25","author":"Canavan","year":"1931","journal-title":"Arch. Neurpsych"},{"key":"10.1016\/j.ymthe.2025.04.045_bib335","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0887-8994(97)00185-9","article-title":"The clinical course of Canavan disease","volume":"18","author":"Traeger","year":"1998","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib336","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13023-020-01659-3","article-title":"The natural history of Canavan disease: 23 new cases and comparison with patients from literature","volume":"16","author":"Bley","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2025.04.045_bib337","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ajmg.1320290234","article-title":"Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease","volume":"29","author":"Matalon","year":"1988","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.ymthe.2025.04.045_bib338","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/ng1093-118","article-title":"Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease","volume":"5","author":"Kaul","year":"1993","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.04.045_bib339","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/00005072-196610000-00007","article-title":"Fine structure of spongy degeneration of the central nervous system (van Bogaert and Bertrand type)","volume":"25","author":"Adachi","year":"1966","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib340","first-page":"164","article-title":"Ultramicroscopic and histochemical studies of spongy degeneration (van Bogaert and Bertrand type)","volume":"26","author":"Adachi","year":"1967","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib341","first-page":"487","article-title":"Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease","volume":"1","author":"Leone","year":"1999","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib342","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/1531-8249(200007)48:1<27::AID-ANA6>3.0.CO;2-6","article-title":"Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease","volume":"48","author":"Leone","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib343","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003454","article-title":"Long-term follow-up after gene therapy for canavan disease","volume":"4","author":"Leone","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib344","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/(SICI)1521-2254(200005\/06)2:3<165::AID-JGM107>3.0.CO;2-R","article-title":"Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system","volume":"2","author":"Matalon","year":"2000","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib345","doi-asserted-by":"crossref","first-page":"11537","DOI":"10.1523\/JNEUROSCI.1490-08.2008","article-title":"Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS","volume":"28","author":"Traka","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymthe.2025.04.045_bib346","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020336","article-title":"Aspartoacylase-lacZ knockin mice: an engineered model of Canavan disease","volume":"6","author":"Mersmann","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2025.04.045_bib347","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/mt.2013.138","article-title":"A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice","volume":"21","author":"Ahmed","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib348","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/mt.2016.68","article-title":"rAAV Gene Therapy in a Canavan\u2019s Disease Mouse Model Reveals Immune Impairments and an Extended Pathology Beyond the Central Nervous System","volume":"24","author":"Ahmed","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib349","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90807","article-title":"Redirecting N-acetylaspartate metabolism in the central nervous system normalizes myelination and rescues Canavan disease","volume":"2","author":"Gessler","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.04.045_bib350","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00401-017-1784-9","article-title":"Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy","volume":"135","author":"von Jonquieres","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib351","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ana.25674","article-title":"Antisense oligonucleotide reverses leukodystrophy in canavan disease mice","volume":"87","author":"Hull","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib352","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.omtm.2021.01.009","article-title":"Preclinical biodistribution, tropism, and efficacy of oligotropic AAV\/Olig001 in a mouse model of congenital white matter disease","volume":"20","author":"Francis","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib353","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.1061257","article-title":"Dual-function AAV gene therapy reverses late-stage Canavan disease pathology in mice","volume":"15","author":"Fr\u00f6hlich","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ymthe.2025.04.045_bib354","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2023.102460","article-title":"Renewal of oligodendrocyte lineage reverses dysmyelination and CNS neurodegeneration through corrected N-acetylaspartate metabolism","volume":"226","author":"Lotun","year":"2023","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib355","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.04.045_bib356","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1073\/pnas.0937739100","article-title":"Adeno-associated viruses undergo substantial evolution in primates during natural infections","volume":"100","author":"Gao","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.04.045_bib357","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","article-title":"Clades of Adeno-associated viruses are widely disseminated in human tissues","volume":"78","author":"Gao","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib358","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib359","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/mt.2014.68","article-title":"Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10","volume":"22","author":"Yang","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib360","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.omtm.2023.06.001","article-title":"Adeno-associated virus-mediated gene therapy in a patient with Canavan disease using dual routes of administration and immune modulation","volume":"30","author":"Corti","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib361","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1212\/WNL.62.7.1058","article-title":"Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis","volume":"62","author":"Pons","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.04.045_bib362","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymgme.2019.03.009","article-title":"Aromatic amino acid decarboxylase deficiency: Molecular and metabolic basis and therapeutic outlook","volume":"127","author":"Himmelreich","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.04.045_bib363","first-page":"1","article-title":"Natural History of Aromatic L-Amino Acid Decarboxylase Deficiency in Taiwan","volume":"40","author":"Hwu","year":"2018","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymthe.2025.04.045_bib364","first-page":"387","article-title":"Aromatic l-amino acid decarboxylase deficiency in Taiwan","volume":"64","author":"Hwu","year":"2023","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymthe.2025.04.045_bib365","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","article-title":"Safety and tolerability of putaminal AADC gene therapy for Parkinson disease","volume":"73","author":"Christine","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.04.045_bib366","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/mt.2010.135","article-title":"A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson\u2019s disease","volume":"18","author":"Muramatsu","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib367","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003640","article-title":"Gene therapy for aromatic L-amino acid decarboxylase deficiency","volume":"4","author":"Hwu","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib368","first-page":"265","article-title":"Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1\/2 trial. Lancet Child Adolesc","volume":"1","author":"Chien","year":"2017","journal-title":"Health"},{"key":"10.1016\/j.ymthe.2025.04.045_bib369","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ymthe.2021.11.005","article-title":"Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency","volume":"30","author":"Tai","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib370","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/ana.25467","article-title":"Gene therapy improves brain white matter in aromatic l-amino acid decarboxylase deficiency","volume":"85","author":"Tseng","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib371","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/brain\/awy331","article-title":"Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency","volume":"142","author":"Kojima","year":"2019","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.04.045_bib372","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114712","article-title":"Gene therapy in the putamen for curing AADC deficiency and Parkinson\u2019s disease","volume":"13","author":"Hwu","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib373","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/1566523221666210922155413","article-title":"Reduced Immunogenicity of Intraparenchymal Delivery of Adeno-Associated Virus Serotype 2 Vectors: Brief Overview","volume":"22","author":"Hwu","year":"2022","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib374","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13023-024-03019-x","article-title":"A position statement on the post gene-therapy rehabilitation of aromatic I-amino acid decarboxylase deficiency patients","volume":"19","author":"Lee","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2025.04.045_bib375","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1007\/s00431-023-04886-5","article-title":"Aromatic L-amino acid decarboxylase deficiency in countries in the Middle East: a case series and literature review","volume":"182","author":"Abukhaled","year":"2023","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymthe.2025.04.045_bib376","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107687","article-title":"Streamlined determination of 3-O-methyldopa in dried blood spots: Prospective screening for aromatic l-amino-acid decarboxylase deficiency","volume":"140","author":"Chen","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.04.045_bib377","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108148","article-title":"Newborn screening for aromatic l-amino acid decarboxylase deficiency - Strategies, results, and implication for prevalence calculations","volume":"141","author":"Reischl-Hajiabadi","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.04.045_bib378","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1167\/tvst.10.4.3","article-title":"Inflammation in Viral Vector-Mediated Ocular Gene Therapy: A Review and Report From a Workshop Hosted by the Foundation Fighting Blindness, 9\/2020","volume":"10","author":"Chan","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib379","series-title":"GeneReviews\u00ae","article-title":"Leber Congenital Amaurosis\/Early-Onset Severe Retinal Dystrophy Overview","author":"Kumaran","year":"1993"},{"key":"10.1016\/j.ymthe.2025.04.045_bib380","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on Leber\u2019s congenital amaurosis","volume":"372","author":"Bainbridge","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib381","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1412965","article-title":"Improvement and decline in vision with gene therapy in childhood blindness","volume":"372","author":"Jacobson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib382","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.04.045_bib383","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.oret.2021.03.016","article-title":"Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis","volume":"6","author":"Gange","year":"2022","journal-title":"Ophthalmol. Retina"},{"key":"10.1016\/j.ymthe.2025.04.045_bib384","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011306","article-title":"Functional and behavioral restoration of vision by gene therapy in the guanylate cyclase-1 (GC1) knockout mouse","volume":"5","author":"Boye","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2025.04.045_bib385","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1089\/hum.2012.193","article-title":"AAV-mediated gene therapy in the guanylate cyclase (RetGC1\/RetGC2) double knockout mouse model of Leber congenital amaurosis","volume":"24","author":"Boye","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib386","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1089\/hum.2011.069","article-title":"Long-term preservation of cones and improvement in visual function following gene therapy in a mouse model of leber congenital amaurosis caused by guanylate cyclase-1 deficiency","volume":"22","author":"Mihelec","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib387","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/hum.2015.053","article-title":"Gene Therapy Fully Restores Vision to the All-Cone Nrl(-\/-) Gucy2e(-\/-) Mouse Model of Leber Congenital Amaurosis-1","volume":"26","author":"Boye","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.045_bib388","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0140-6736(24)01447-8","article-title":"Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1\/2, multicentre, open-label, unilateral dose escalation study","volume":"404","author":"Yang","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.04.045_bib389","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.omtm.2022.12.007","article-title":"Preclinical studies in support of phase I\/II clinical trials to treat GUCY2D-associated Leber congenital amaurosis","volume":"28","author":"Boye","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.045_bib390","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105274","article-title":"Night vision restored in days after decades of congenital blindness","volume":"25","author":"Jacobson","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.ymthe.2025.04.045_bib391","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene Editing for CEP290-Associated Retinal Degeneration","volume":"390","author":"Pierce","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.045_bib392","first-page":"3318","article-title":"Five-year results after AAV2-REP1 gene therapy for choroideremia","volume":"62","author":"Zhai","year":"2021","journal-title":"Nvest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2025.04.045_bib393","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.04.045_bib394","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2018.06.011","article-title":"Two-Year Results After AAV2-Mediated Gene Therapy for Choroideremia: The Alberta Experience","volume":"193","author":"Dimopoulos","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib395","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ajo.2018.09.012","article-title":"Choroideremia Gene Therapy Phase 2 Clinical Trial: 24-Month Results","volume":"197","author":"Lam","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib396","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nature05161","article-title":"Retinal repair by transplantation of photoreceptor precursors","volume":"444","author":"MacLaren","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.04.045_bib397","author":"Kay"},{"key":"10.1016\/j.ymthe.2025.04.045_bib398","article-title":"Efficacy and Safety of rAAV2-ND4 Treatment for Leber\u2019s Hereditary Optic Neuropathy","volume":"6","author":"Wan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.04.045_bib399","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ophtha.2020.12.012","article-title":"Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset","volume":"128","author":"Newman","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2025.04.045_bib400","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/WNO.0000000000001367","article-title":"Long-Term Follow-Up After Unilateral Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy: The RESTORE Study","volume":"41","author":"Biousse","year":"2021","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib401","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ajo.2023.09.005","article-title":"Leber hereditary optic neuropathy gene therapy: longitudinal relationships among visual function and anatomical measures","volume":"257","author":"Lam","year":"2024","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib402","first-page":"2829","article-title":"Interim Safety Results in Two Phase 1\/2 Open-label, Dose-escalation Clinical Trials of Subretinal Gene Therapy with AGTC-401 (rAAV2tYF-PR1.7-hCNGB3) and AGTC-402 (rAAV2tYF-PR1.7-hCNGA3) in Subjects with Achromatopsia (ACHM)","volume":"63","author":"Iannaccone","year":"2022","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2025.04.045_bib403","first-page":"450","article-title":"Findings on visual photosensitivity in two phase 1\/2 clinical trials of subretinal gene therapy with AGTC-401 and AGTC-402 for CNGB3 and CNGA3 achromatopsia","volume":"63","author":"Huckfeldt","year":"2022","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2025.04.045_bib404","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaophthalmol.2020.1032","article-title":"Safety and vision outcomes of subretinal gene therapy targeting cone photoreceptors in achromatopsia: A nonrandomized controlled trial","volume":"138","author":"Fischer","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib405","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ajo.2023.05.009","article-title":"First-in-Human Gene Therapy Trial of AAV8-hCARp.hCNGB3 in Adults and Children With CNGB3-associated Achromatopsia","volume":"253","author":"Michaelides","year":"2023","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2025.04.045_bib407","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1038\/s41467-023-42386-0","article-title":"mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy","volume":"14","author":"Riedmayr","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.045_bib408","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exer.2015.06.007","article-title":"RPGR: Its role in photoreceptor physiology, human disease, and future therapies","volume":"138","author":"Megaw","year":"2015","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ymthe.2025.04.045_bib409","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2174\/138920211795860107","article-title":"Retinitis pigmentosa: genes and disease mechanisms","volume":"12","author":"Ferrari","year":"2011","journal-title":"Curr. Genomics"},{"key":"10.1016\/j.ymthe.2025.04.045_bib411","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.exer.2019.05.006","article-title":"The role of complement membrane attack complex in dry and wet AMD - From hypothesis to clinical trials","volume":"184","author":"Kumar-Singh","year":"2019","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ymthe.2025.04.045_bib412","first-page":"1504","article-title":"Preliminary Results from a First-in-human Phase I\/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration","volume":"63","author":"Nielsen","year":"2022","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2025.04.045_bib413","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ebiom.2016.11.016","article-title":"Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration","volume":"14","author":"Constable","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2025.04.045_bib414","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","article-title":"Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial","volume":"390","author":"Heier","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.04.045_bib415","first-page":"1154","article-title":"Phase 1 Study of Intravitreal Gene Therapy ADVM-022 for neovascular AMD (OPTIC Trial)","volume":"61","author":"Khanani","year":"2020","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2025.04.045_bib416","first-page":"352","article-title":"Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for neovascular AMD (OPTIC Trial)","volume":"62","author":"Busbee","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2025.04.045_bib417","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1301915","article-title":"Bibliometric analysis of global research trends in adeno-associated virus vector for gene therapy (1991-2022)","volume":"13","author":"Jiang","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162500365X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162500365X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T21:10:44Z","timestamp":1759612244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162500365X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":399,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S152500162500365X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.045","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current clinical applications of AAV-mediated gene therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}